Pancreatic Cancer Research

Clinical trialPhase 1 / Phase 2Completed

A Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Participants With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)

A Phase 1/2, Open-Label, Safety, Tolerability, and Efficacy Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)

Outcome
Results posted; no analysis attached
Phase
Phase 1 / Phase 2
Status
Completed
Study type
Interventional
Start
2 May 2017
Ended
13 July 2020
Enrollment
70 participants
Sites
16
Primary outcomes
Phases 1 & 2: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs; Phases 1 and 2: Number of Participants With Dose Limiting Toxicities (DLTs); Phases 1 and 2: Objective Response Rate (ORR)
Sponsor type
Industry
Results posted
7 May 2020
Last update
23 September 2022

These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.

Results

Primary endpoint
Results posted; no analysis attachedAs posted on ClinicalTrials.gov ↗, registry record of 23 September 2022
Primary outcome
Phases 1 & 2: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEsTEAE: Group A: Epa + Pembrolizumab + mFOLFOX6: 9 of 9TEAE: Group B: Epa + Pembrolizumab + Nab-Paclitaxel and Gemcitabine: 9 of 9TEAE: Group C: Epa + Pembrolizumab + Paclitaxel and Carboplatin: 11 of 11TEAE: Group D: Epa + Pembrolizumab + Pemetrexed and Platinum Agent: 9 of 9TEAE: Group E: Epa + Pembrolizumab + Cyclophosphamide: 13 of 13TEAE: Group F: Epa + Pembrolizumab + Gemcitabine and Platinum Agent: 8 of 8TEAE: Group G: Epa + Pembrolizumab + 5-FU and Platinum Agent: 11 of 11Serious TEAE: Group A: Epa + Pembrolizumab + mFOLFOX6: 5 of 9Serious TEAE: Group B: Epa + Pembrolizumab + Nab-Paclitaxel and Gemcitabine: 5 of 9Serious TEAE: Group C: Epa + Pembrolizumab + Paclitaxel and Carboplatin: 3 of 11Serious TEAE: Group D: Epa + Pembrolizumab + Pemetrexed and Platinum Agent: 6 of 9Serious TEAE: Group E: Epa + Pembrolizumab + Cyclophosphamide: 4 of 13Serious TEAE: Group F: Epa + Pembrolizumab + Gemcitabine and Platinum Agent: 6 of 8Serious TEAE: Group G: Epa + Pembrolizumab + 5-FU and Platinum Agent: 5 of 11Values: ParticipantsTime frame: Up to 21 monthsNo analysis posted for this outcome (outcome 1)
DLT/MTD
Phases 1 and 2: Number of Participants With Dose Limiting Toxicities (DLTs)Group A: Epa + Pembrolizumab + mFOLFOX6: 2 of 9Group B: Epa + Pembrolizumab + Nab-Paclitaxel and Gemcitabine: 0 of 9Group C: Epa + Pembrolizumab + Paclitaxel and Carboplatin: 0 of 11Group D: Epa + Pembrolizumab + Pemetrexed and Platinum Agent: 0 of 9Group E: Epa + Pembrolizumab + Cyclophosphamide: 0 of 13Group F: Epa + Pembrolizumab + Gemcitabine and Platinum Agent: 3 of 8Group G: Epa + Pembrolizumab + 5-FU and Platinum Agent: 0 of 11Values: ParticipantsTime frame: 28 daysNo analysis posted for this outcome (outcome 2)
ORR
Phases 1 and 2: Objective Response Rate (ORR)Complete Response: Group A: Epa + Pembrolizumab + mFOLFOX6: 0 of 9Complete Response: Group B: Epa + Pembrolizumab + Nab-Paclitaxel and Gemcitabine: 1 of 9Complete Response: Group C: Epa + Pembrolizumab + Paclitaxel and Carboplatin: 0 of 11Complete Response: Group D: Epa + Pembrolizumab + Pemetrexed and Platinum Agent: 0 of 9Complete Response: Group E: Epa + Pembrolizumab + Cyclophosphamide: 0 of 13Complete Response: Group F: Epa + Pembrolizumab + Gemcitabine and Platinum Agent: 0 of 8Complete Response: Group G: Epa + Pembrolizumab + 5-FU and Platinum Agent: 0 of 11Partial Response: Group A: Epa + Pembrolizumab + mFOLFOX6: 5 of 9Partial Response: Group B: Epa + Pembrolizumab + Nab-Paclitaxel and Gemcitabine: 2 of 9Partial Response: Group C: Epa + Pembrolizumab + Paclitaxel and Carboplatin: 3 of 11Partial Response: Group D: Epa + Pembrolizumab + Pemetrexed and Platinum Agent: 2 of 9Partial Response: Group E: Epa + Pembrolizumab + Cyclophosphamide: 3 of 13Partial Response: Group F: Epa + Pembrolizumab + Gemcitabine and Platinum Agent: 1 of 8Partial Response: Group G: Epa + Pembrolizumab + 5-FU and Platinum Agent: 5 of 11Values: ParticipantsTime frame: Up to Week 18No analysis posted for this outcome (outcome 3)
Participants
Group A: Epa + Pembrolizumab +mFOLFOX6: 9 started, 0 completedGroup B: Epa + Pembrolizumab + Nab-Paclitaxel and Gemcitabine: 9 started, 0 completedGroup C: Epa + Pembrolizumab + Paclitaxel and Carboplatin: 11 started, 0 completedGroup D: Epa + Pembrolizumab + Pemetrexed and Platinum Agent: 9 started, 0 completedGroup E: Epa + Pembrolizumab + Cyclophosphamide: 13 started, 0 completedGroup F: Epa + Pembrolizumab + Gemcitabine and Platinum Agent: 8 started, 0 completedGroup G: Epa + Pembrolizumab + 5-FU and Platinum Agent: 11 started, 0 completed
Serious adverse events
Group A: Epa + Pembrolizumab + mFOLFOX6: 5 of 9Group B: Epa + Pembrolizumab + Nab-Paclitaxel and Gemcitabine: 5 of 9Group C: Epa + Pembrolizumab + Paclitaxel and Carboplatin: 5 of 11Group D: Epa + Pembrolizumab + Pemetrexed and Platinum Agent: 3 of 9Group E: Epa + Pembrolizumab + Cyclophosphamide: 6 of 13Group F: Epa + Pembrolizumab + Gemcitabine and Platinum Agent: 4 of 8Group G: Epa + Pembrolizumab + 5-FU and Platinum Agent: 6 of 11Total: 34 of 70Participants with at least one serious adverse event, of those at risk, as posted

Every value is copied from the trial’s results record at ClinicalTrials.gov. “Statistically significant” describes the posted test only: it does not say which group did better, and nothing here is read from a paper.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

This was an open-label, nonrandomized, Phase 1/2 study designed to determine the safety, tolerability, and efficacy of epacadostat when given in combination with pembrolizumab and 7 different chemotherapy regimens described as Treatment Groups A through G below (see Study Drug and Background Therapies, Dose, and Mode of Administration). Phase 1 consisted of a 3 + 3 + 3 design intended to determine the MTD or PAD of epacadostat when given in combination with pembrolizumab and chemotherapy; efficacy was also explored. Phase 2 was designed to enroll efficacy expansion cohorts to further evaluate the safety, tolerability, and efficacy of epacadostat at the MTD or PAD (as selected in Phase 1) when given in combination with pembrolizumab and chemotherapy. Each efficacy expansion cohort was to enroll participants with 1 specific type of advanced or metastatic solid tumor. Additional cohorts (ie, the mandatory biopsy cohorts) were designed to evaluate changes in the tumor microenvironment in participants with any advanced or metastatic solid tumor who had progressed on previous therapy with a PD-1 or a PD-L1 inhibitor. No participants were enrolled in any Phase 2 efficacy expansion cohort, or in any Phase 2 mandatory biopsy cohort receiving Treatment A, B, F, or G. Phase 2 mandatory biopsy cohort participants received Treatments C, D, or E (ie, were included in Treatment Groups C, D, or E). Participants were assigned to a treatment group based on the chemotherapy regimen most appropriate for their tumor type.

Posted results (ClinicalTrials.gov registry) · primary outcome public domain (ClinicalTrials.gov)

Phases 1 & 2: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs [Up to 21 months]. Count Of Participants, Participants. TEAE: Group A: Epa + Pembrolizumab + mFOLFOX6 (n=9): 9; Group B: Epa + Pembrolizumab + Nab-Paclitaxel and Gemcitabine (n=9): 9; Group C: Epa + Pembrolizumab + Paclitaxel and Carboplatin (n=11): 11; Group D: Epa + Pembrolizumab + Pemetrexed and Platinum Agent (n=9): 9; Group E: Epa + Pembrolizumab + Cyclophosphamide (n=13): 13; Group F: Epa + Pembrolizumab + Gemcitabine and Platinum Agent (n=8): 8; Group G: Epa + Pembrolizumab + 5-FU and Platinum Agent (n=11): 11. Serious TEAE: Group A: Epa + Pembrolizumab + mFOLFOX6 (n=9): 5; Group B: Epa + Pembrolizumab + Nab-Paclitaxel and Gemcitabine (n=9): 5; Group C: Epa + Pembrolizumab + Paclitaxel and Carboplatin (n=11): 3; Group D: Epa + Pembrolizumab + Pemetrexed and Platinum Agent (n=9): 6; Group E: Epa + Pembrolizumab + Cyclophosphamide (n=13): 4; Group F: Epa + Pembrolizumab + Gemcitabine and Platinum Agent (n=8): 6; Group G: Epa + Pembrolizumab + 5-FU and Platinum Agent (n=11): 5.

Posted results (ClinicalTrials.gov registry) · primary outcome public domain (ClinicalTrials.gov)

Phases 1 and 2: Number of Participants With Dose Limiting Toxicities (DLTs) [28 days]. Count Of Participants, Participants. Group A: Epa + Pembrolizumab + mFOLFOX6 (n=9): 2; Group B: Epa + Pembrolizumab + Nab-Paclitaxel and Gemcitabine (n=9): 0; Group C: Epa + Pembrolizumab + Paclitaxel and Carboplatin (n=11): 0; Group D: Epa + Pembrolizumab + Pemetrexed and Platinum Agent (n=9): 0; Group E: Epa + Pembrolizumab + Cyclophosphamide (n=13): 0; Group F: Epa + Pembrolizumab + Gemcitabine and Platinum Agent (n=8): 3; Group G: Epa + Pembrolizumab + 5-FU and Platinum Agent (n=11): 0.

Posted results (ClinicalTrials.gov registry) · primary outcome public domain (ClinicalTrials.gov)

Phases 1 and 2: Objective Response Rate (ORR) [Up to Week 18]. Count Of Participants, Participants. Complete Response: Group A: Epa + Pembrolizumab + mFOLFOX6 (n=9): 0; Group B: Epa + Pembrolizumab + Nab-Paclitaxel and Gemcitabine (n=9): 1; Group C: Epa + Pembrolizumab + Paclitaxel and Carboplatin (n=11): 0; Group D: Epa + Pembrolizumab + Pemetrexed and Platinum Agent (n=9): 0; Group E: Epa + Pembrolizumab + Cyclophosphamide (n=13): 0; Group F: Epa + Pembrolizumab + Gemcitabine and Platinum Agent (n=8): 0; Group G: Epa + Pembrolizumab + 5-FU and Platinum Agent (n=11): 0. Partial Response: Group A: Epa + Pembrolizumab + mFOLFOX6 (n=9): 5; Group B: Epa + Pembrolizumab + Nab-Paclitaxel and Gemcitabine (n=9): 2; Group C: Epa + Pembrolizumab + Paclitaxel and Carboplatin (n=11): 3; Group D: Epa + Pembrolizumab + Pemetrexed and Platinum Agent (n=9): 2; Group E: Epa + Pembrolizumab + Cyclophosphamide (n=13): 3; Group F: Epa + Pembrolizumab + Gemcitabine and Platinum Agent (n=8): 1; Group G: Epa + Pembrolizumab + 5-FU and Platinum Agent (n=11): 5.